Deep learning-driven drug response prediction and mechanistic insights in cancer genomics

Abstract excerpt

In the field of cancer therapy, the diversity and heterogeneity of cancer genomes in clinical patients complicate and challenge the effective use of non-targeted drugs, as these drugs often fail to address specific genetic events. Recent advancements in large-scale in vitro drug screening assays have generated extensive drug testing and genomic data, providing valuable resources to explore the relationship...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to Genetics, Bioinformatics, and Biomedical Research
• Share to PARP inhibition in cancer therapy